Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Treasury Shares: 2021-2024

Historic Treasury Shares for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $2.7 billion.

  • ProQR Therapeutics N.V's Treasury Shares rose 98121.09% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 98121.09%. This contributed to the annual value of $2.7 billion for FY2024, which is 85188.82% up from last year.
  • ProQR Therapeutics N.V's Treasury Shares amounted to $2.7 billion in FY2024, which was up 85,188.82% from $3.1 million recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Treasury Shares high stood at $2.7 billion for FY2024, and its period low was $3.1 million during FY2023.
  • For the 3-year period, ProQR Therapeutics N.V's Treasury Shares averaged around $892.1 million, with its median value being $3.5 million (2022).
  • Its Treasury Shares has fluctuated over the past 5 years, first dropped by 17.28% in 2022, then surged by 85,188.82% in 2024.
  • Yearly analysis of 4 years shows ProQR Therapeutics N.V's Treasury Shares stood at $4.2 million in 2021, then decreased by 17.28% to $3.5 million in 2022, then decreased by 10.55% to $3.1 million in 2023, then soared by 85,188.82% to $2.7 billion in 2024.